AGIO - アギオス・ファ―マシュ―ティカルズ (Agios Pharmaceuticals Inc.)

AGIOのニュース

   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors  2021/03/01 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb. “We
   Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results  2021/02/26 21:49:29 Transcript Daily
Agios Pharmaceuticals (NASDAQ:AGIO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.31) by ($0.10), MarketWatch Earnings reports. The firm had revenue of $39.10 million for the quarter, compared to the consensus estimate of $39.86 million. Agios Pharmaceuticals had […]
   Canaccord Genuity Stick to Their Buy Rating for Agios Pharma By Investing.com  2021/02/26 11:37:51 Investing.com
Canaccord Genuity Stick to Their Buy Rating for Agios Pharma
   Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report 2021 - Key Players Involved are Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, & Agios Pharmaceuticals - ResearchAndMarkets.com  2021/02/19 10:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Relapsed or Refractory Myelodysplastic Syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.

calendar